We are live on ! Find out more
STXS icon

Stereotaxis

1.31 USD
-0.02
1.5%
At close Updated Sep 15, 2:36 PM EDT
1 day
-1.5%
5 days
1.55%
1 month
-5.76%
3 months
-28.8%
6 months
-31.41%
Year to date
-43.53%
1 year
-53.55%
5 years
-77.06%
10 years
-60.78%
 

About: Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems, Disposables, Royalty, and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.

Employees: 131

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 12.5%
Neutral 75%
Negative 12.5%
Neutral
GlobeNewsWire
12 days ago
University of Szeged Celebrates Strongest First Month of Robotic Cardiology Program
ST. LOUIS, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that the Electrophysiology team at the University of Szeged in Hungary has successfully treated over 70 patients using the Genesis Robotic Magnetic Navigation system, just over a month after launching its robotic cardiology program.
University of Szeged Celebrates Strongest First Month of Robotic Cardiology Program
Neutral
Seeking Alpha
1 month ago
Stereotaxis, Inc. (STXS) Q2 2026 Earnings Call Transcript
Stereotaxis, Inc. (STXS) Q2 2026 Earnings Call Transcript
Stereotaxis, Inc. (STXS) Q2 2026 Earnings Call Transcript
Positive
MarketBeat
1 month ago
Stereotaxis Q2 Earnings Call Highlights
Stereotaxis NYSEAMERICAN: STXS reported second-quarter 2026 revenue of $7.7 million, as growth in sales of its robotic catheter portfolio helped lift recurring revenue to a multiyear high despite lower system revenue and continued supply constraints.
Stereotaxis Q2 Earnings Call Highlights
Negative
Zacks Investment Research
1 month ago
Stereotaxis Inc. (STXS) Reports Q2 Loss, Lags Revenue Estimates
Stereotaxis Inc. (STXS) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to a loss of $0.05 per share a year ago.
Stereotaxis Inc. (STXS) Reports Q2 Loss, Lags Revenue Estimates
Neutral
GlobeNewsWire
1 month ago
Stereotaxis Reports 2026 Second Quarter Financial Results & Business Updates
ST. LOUIS, Mo., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported business updates and financial results for the second quarter ended June 30, 2026.
Stereotaxis Reports 2026 Second Quarter Financial Results & Business Updates
Neutral
GlobeNewsWire
1 month ago
Stereotaxis to Report Second Quarter 2026 Financial Results on August 11, 2026
ST. LOUIS, July 21, 2026 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2026 second quarter on Tuesday, August 11, 2026 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m.
Stereotaxis to Report Second Quarter 2026 Financial Results on August 11, 2026
Neutral
GlobeNewsWire
1 month ago
University of Szeged Pioneers First Robotic Cardiology Program in Hungary
First Robotic Magnetic Navigation system installed in Hungary University of Szeged, led by Cardiology Chief Dr. Szili-Torok, expected to treat hundreds of patients annually with all forms of cardiac arrhythmia using precision of robotics ST. LOUIS, July 20, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the launch of the first advanced robotic cardiology program in Hungary at the University of Szeged in Szeged, Hungary.
University of Szeged Pioneers First Robotic Cardiology Program in Hungary
Neutral
GlobeNewsWire
2 months ago
Stereotaxis Completes Acquisition of Robocath
ST. LOUIS and ROUEN, France, July 09, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has completed its previously announced acquisition of Robocath, an innovator of robotic technologies for interventional cardiology and neurointerventions.
Stereotaxis Completes Acquisition of Robocath
Positive
MarketBeat
4 months ago
Stereotaxis Q1 Earnings Call Highlights
Stereotaxis NYSEAMERICAN: STXS said its first-quarter results did not yet reflect what management described as a major commercial transition driven by new regulatory approvals, new catheter products and the launch of its GenesisX robotic system.
Stereotaxis Q1 Earnings Call Highlights
Neutral
Seeking Alpha
4 months ago
Stereotaxis, Inc. (STXS) Q1 2026 Earnings Call Transcript
Stereotaxis, Inc. (STXS) Q1 2026 Earnings Call Transcript
Stereotaxis, Inc. (STXS) Q1 2026 Earnings Call Transcript
Price charts implemented using Lightweight Charts™